NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Brookside Capital’

22 January 2014

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

dna Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

4 December 2013

Biotech company Zafgen raises $45m Series E

biotech_lrg Biopharmaceutical business Zafgen has raised $45m in a Series E round to fund the development of its obesity therapeutic beloranib.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

dna RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

8 May 2013

Venture-backed biopharma Portola eyes $127m Nasdaq IPO

Venture-backed biopharmaceutical company Portola Pharmaceuticals is targeting $127m from its listing on Nasdaq.


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014